Skip to main content
Top
Published in: Diabetologia 8/2003

01-08-2003 | Article

Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents

Authors: C. Gysemans, K. Stoffels, A. Giulietti, L. Overbergh, M. Waer, M. Lannoo, U. Feige, Dr. C. Mathieu

Published in: Diabetologia | Issue 8/2003

Login to get access

Abstract

Aims/hypothesis

High levels of inflammation locally in the graft during the initial days after transplantation can cause primary non-function (PNF) of grafted xenogeneic islets in NOD mice. The aim of this study was to explore in a model of spontaneous diabetes, the NOD mouse, the potential of anti-inflammatory agents in the prevention of PNF after xenogeneic islet transplantation.

Methods

Spontaneously diabetic NOD mice were transplanted with 300 rat islets. Animals were treated with acetylsalicylic acid (AsA), rofecoxib, TGF-β or IL-1 receptor antagonist (IL-1ra). Intra-graft expression of inflammation-related molecules was measured by real time PCR 8 h post-transplantation. At the same time point, plasma nitrite levels were measured.

Results

Xenogeneic islets transplanted in control spontaneously diabetic mice resulted in PNF in 16 out of 38 mice (42%). Initial graft loss was not altered by administration of rofecoxib (30%) or TGF-β (25%). AsA reduced the rate of rapid graft loss to 8% (p<0.05 vs controls) and administration of IL-1ra even totally prevented PNF (0%, p<0.05 vs controls). Furthermore, all therapies prolonged the mean survival time of xenogeneic islet grafts. The inhibition of PNF by AsA was associated with decreased intra-islet levels of inflammation-related molecules (IL-1, TNF-α, iNOS, COX-2) and chemokines (MCP-1 and MIP-3α). Finally, also a diminished production of systemic nitrite levels was observed in AsA- and IL-1ra-treated islet recipients.

Conclusions/Interpretation

These data show that treatment with AsA or IL-1ra prevents PNF after islet transplantation in spontaneously diabetic NOD mice. Moreover, the involvement of non-specific inflammation is recognized in xenogeneic islet PNF in spontaneously diabetic NOD mice.
Literature
1.
go back to reference Bretzel RG, Hering BJ, Federlin KF (1995) Islet cell transplantation in diabetes mellitus—from bench to bedside. Exp Clin Endocrinol Diabetes 103 [Suppl 2]:143–159 Bretzel RG, Hering BJ, Federlin KF (1995) Islet cell transplantation in diabetes mellitus—from bench to bedside. Exp Clin Endocrinol Diabetes 103 [Suppl 2]:143–159
2.
go back to reference Samuel T, Cockwell P (2002) Islet cell transplantation. J R Soc Med 95 1:31–33CrossRef Samuel T, Cockwell P (2002) Islet cell transplantation. J R Soc Med 95 1:31–33CrossRef
3.
go back to reference Shapiro AM, Lakey JR, Ryan EA et al. (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230–238PubMed Shapiro AM, Lakey JR, Ryan EA et al. (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230–238PubMed
4.
go back to reference Ryan EA, Lakey JR, Rajotte RV et al. (2001) Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 50:710–719PubMed Ryan EA, Lakey JR, Rajotte RV et al. (2001) Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 50:710–719PubMed
5.
go back to reference Pipeleers D, Keymeulen B, Chatenoud L et al. (2002) A view on beta cell transplantation in diabetes. Ann NY Acad Sci 958:69–76PubMed Pipeleers D, Keymeulen B, Chatenoud L et al. (2002) A view on beta cell transplantation in diabetes. Ann NY Acad Sci 958:69–76PubMed
6.
go back to reference Kendall WF Jr, Collins BH, Opara EC (2001) Islet cell transplantation for the treatment of diabetes mellitus. Expert Opin Biol Ther 1:109–119PubMed Kendall WF Jr, Collins BH, Opara EC (2001) Islet cell transplantation for the treatment of diabetes mellitus. Expert Opin Biol Ther 1:109–119PubMed
7.
go back to reference Wallgren AC, Karlsson-Parra A, Korsgren O (1995) The main infiltrating cell in xenograft rejection is a CD4+ macrophage and not a T lymphocyte. Transplantation 60:594–601PubMed Wallgren AC, Karlsson-Parra A, Korsgren O (1995) The main infiltrating cell in xenograft rejection is a CD4+ macrophage and not a T lymphocyte. Transplantation 60:594–601PubMed
8.
go back to reference Yi S, Feng X, Hawthorne WJ, Patel AT, Walters SN, O'Connell PJ (2002) CD4+ T cells initiate pancreatic islet xenograft rejection via an interferon-gamma-dependent recruitment of macrophages and natural killer cells. Transplantation 73:437–446PubMed Yi S, Feng X, Hawthorne WJ, Patel AT, Walters SN, O'Connell PJ (2002) CD4+ T cells initiate pancreatic islet xenograft rejection via an interferon-gamma-dependent recruitment of macrophages and natural killer cells. Transplantation 73:437–446PubMed
9.
go back to reference Brauker J, Martinson LA, Young SK, Johnson RC (1996) Local inflammatory response around diffusion chambers containing xenografts. Nonspecific destruction of tissues and decreased local vascularization. Transplantation 61:1671–1677PubMed Brauker J, Martinson LA, Young SK, Johnson RC (1996) Local inflammatory response around diffusion chambers containing xenografts. Nonspecific destruction of tissues and decreased local vascularization. Transplantation 61:1671–1677PubMed
10.
go back to reference Deng S, Ketchum RJ, Kucher T, Weber M, Naji A, Brayman KL (1997) Primary non-function of islet xenografts in rat recipients results from non-T-cell mediated immune responses. Transplant Proc 29:1726–1727CrossRefPubMed Deng S, Ketchum RJ, Kucher T, Weber M, Naji A, Brayman KL (1997) Primary non-function of islet xenografts in rat recipients results from non-T-cell mediated immune responses. Transplant Proc 29:1726–1727CrossRefPubMed
11.
go back to reference Gysemans CA, Waer M, Valckx D et al. (2000) Early graft failure of xenogenic islets in NOD mice is accompanied by high levels of IL-1 and low levels of TGF-β mRNA in the grafts. Diabetes 49:1992–1997PubMed Gysemans CA, Waer M, Valckx D et al. (2000) Early graft failure of xenogenic islets in NOD mice is accompanied by high levels of IL-1 and low levels of TGF-β mRNA in the grafts. Diabetes 49:1992–1997PubMed
12.
go back to reference Alleva DG, Pavlovich RP, Grant C, Kaser SB, Beller DI (2000) Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains. Elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor-α and IL-10 define a unique cytokine profile in macrophages from young NOD mice. Diabetes 49:1106–1115PubMed Alleva DG, Pavlovich RP, Grant C, Kaser SB, Beller DI (2000) Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains. Elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor-α and IL-10 define a unique cytokine profile in macrophages from young NOD mice. Diabetes 49:1106–1115PubMed
13.
go back to reference Charre S, Rosmalen JG, Pelegri C et al. (2002) Abnormalities in dendritic cell and macrophage accumulation in the pancreas of nonobese diabetic (NOD) mice during the early neonatal period. Histol Histopathol 17:393–401PubMed Charre S, Rosmalen JG, Pelegri C et al. (2002) Abnormalities in dendritic cell and macrophage accumulation in the pancreas of nonobese diabetic (NOD) mice during the early neonatal period. Histol Histopathol 17:393–401PubMed
14.
go back to reference O'Brien BA, Huang Y, Geng X, Dutz JP, Finegood DT (2002) Phagocytosis of apoptotic cells by macrophages from NOD mice is reduced. Diabetes 51:2481–2488PubMed O'Brien BA, Huang Y, Geng X, Dutz JP, Finegood DT (2002) Phagocytosis of apoptotic cells by macrophages from NOD mice is reduced. Diabetes 51:2481–2488PubMed
15.
go back to reference Jansen A, Hagen M van, Drexhage HA (1995) Defective maturation and function of antigen-presenting cells in type 1 diabetes. Lancet 345:491–492PubMed Jansen A, Hagen M van, Drexhage HA (1995) Defective maturation and function of antigen-presenting cells in type 1 diabetes. Lancet 345:491–492PubMed
16.
go back to reference Plesner A, Greenbaum CJ, Gaur LK, Ernst RK, Lernmark A (2002) Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccharide stimulation. Scand J Immunol 56:522–529CrossRefPubMed Plesner A, Greenbaum CJ, Gaur LK, Ernst RK, Lernmark A (2002) Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccharide stimulation. Scand J Immunol 56:522–529CrossRefPubMed
17.
go back to reference Vial T, Choquet-Kastylevsky G, Descotes J (2002) Adverse effects of immunotherapeutics involving the immune system. Toxicology 174:3–11CrossRefPubMed Vial T, Choquet-Kastylevsky G, Descotes J (2002) Adverse effects of immunotherapeutics involving the immune system. Toxicology 174:3–11CrossRefPubMed
18.
go back to reference Gysemans C, Waer M, Laureys J, Bouillon R, Mathieu C (2001) A combination of KH1060, a vitamin D(3) analogue, and cyclosporin prevents early graft failure and prolongs graft survival of xenogeneic islets in nonobese diabetic mice. Transplant Proc 33:2365CrossRefPubMed Gysemans C, Waer M, Laureys J, Bouillon R, Mathieu C (2001) A combination of KH1060, a vitamin D(3) analogue, and cyclosporin prevents early graft failure and prolongs graft survival of xenogeneic islets in nonobese diabetic mice. Transplant Proc 33:2365CrossRefPubMed
19.
go back to reference Gysemans C, Waer M, Laureys J, Bouillon R, Mathieu C (2001) Leflunomide and its analogue X920715 synergize with cyclosporin A in preventing early graft failure and delaying graft rejection of xenogeneic islets in nonobese diabetic mice. Transplant Proc 33:2094–2095CrossRefPubMed Gysemans C, Waer M, Laureys J, Bouillon R, Mathieu C (2001) Leflunomide and its analogue X920715 synergize with cyclosporin A in preventing early graft failure and delaying graft rejection of xenogeneic islets in nonobese diabetic mice. Transplant Proc 33:2094–2095CrossRefPubMed
20.
go back to reference Pozzilli P, Signore A, Williams AJ, Beales PE (1993) NOD mouse colonies around the world: recent facts and figures. Immunol Today 14:193–196PubMed Pozzilli P, Signore A, Williams AJ, Beales PE (1993) NOD mouse colonies around the world: recent facts and figures. Immunol Today 14:193–196PubMed
21.
go back to reference Overbergh L, Valckx D, Waer M, Mathieu C (1999) Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 11:305–312CrossRefPubMed Overbergh L, Valckx D, Waer M, Mathieu C (1999) Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine 11:305–312CrossRefPubMed
22.
go back to reference Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C (2001) An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25:386–401CrossRefPubMed Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C (2001) An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25:386–401CrossRefPubMed
23.
go back to reference Cardozo AK, Proost P, Gysemans C, Chen MC, Mathieu C, Eizirik D (2002) IL-1β and IFN-γ induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia 46:255–266 Cardozo AK, Proost P, Gysemans C, Chen MC, Mathieu C, Eizirik D (2002) IL-1β and IFN-γ induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia 46:255–266
24.
go back to reference Falcon M, Sarvetnick N (1999) The effect of local production of cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Clin Immunol 90:2–9CrossRefPubMed Falcon M, Sarvetnick N (1999) The effect of local production of cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Clin Immunol 90:2–9CrossRefPubMed
25.
go back to reference Mathis D, Vence L, Benoist C (2001) β-cell death during progression to diabetes. Nature 414:792–798CrossRefPubMed Mathis D, Vence L, Benoist C (2001) β-cell death during progression to diabetes. Nature 414:792–798CrossRefPubMed
26.
go back to reference Eizirik DL, Mandrup-Poulsen T (2001) A choice of death—the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 44:2115–2133PubMed Eizirik DL, Mandrup-Poulsen T (2001) A choice of death—the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 44:2115–2133PubMed
27.
go back to reference Serreze DV (1993) Autoimmune diabetes results from genetic defects manifest by antigen presenting cells. FASEB J 7:1092–1096PubMed Serreze DV (1993) Autoimmune diabetes results from genetic defects manifest by antigen presenting cells. FASEB J 7:1092–1096PubMed
28.
go back to reference Liu J, Beller D (2002) Aberrant production of IL-12 by macrophages from several autoimmune-prone mouse strains is characterized by intrinsic and unique patterns of NF-kappa B expression and binding to the IL-12 p40 promoter. J Immunol 169:581–586PubMed Liu J, Beller D (2002) Aberrant production of IL-12 by macrophages from several autoimmune-prone mouse strains is characterized by intrinsic and unique patterns of NF-kappa B expression and binding to the IL-12 p40 promoter. J Immunol 169:581–586PubMed
29.
go back to reference Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC (2002) Post-transplantation diabetes: a systematic review of the literature. Diabetes Care 25:583–592PubMed Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC (2002) Post-transplantation diabetes: a systematic review of the literature. Diabetes Care 25:583–592PubMed
30.
go back to reference Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232–235PubMed Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232–235PubMed
31.
go back to reference Gautam SC, Pindolia KR, Noth CJ, Janakiraman N, Xu YX, Chapman RA (1995) Chemokine gene expression in bone marrow stromal cells: down-regulation with sodium salicylate. Blood 86:2541–2550PubMed Gautam SC, Pindolia KR, Noth CJ, Janakiraman N, Xu YX, Chapman RA (1995) Chemokine gene expression in bone marrow stromal cells: down-regulation with sodium salicylate. Blood 86:2541–2550PubMed
32.
go back to reference Sakurada S, Kato T, Okamoto T (1996) Induction of cytokines and ICAM-1 by pro-inflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. Int Immunol 8:1483–1493PubMed Sakurada S, Kato T, Okamoto T (1996) Induction of cytokines and ICAM-1 by pro-inflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. Int Immunol 8:1483–1493PubMed
33.
go back to reference Shackelford RE, Alford PB, Xue Y, Thai SF, Adams DO, Pizzo S (1997) Aspirin inhibits tumor necrosis factor-alpha gene expression in murine tissue macrophages. Mol Pharmacol 52:421–429PubMed Shackelford RE, Alford PB, Xue Y, Thai SF, Adams DO, Pizzo S (1997) Aspirin inhibits tumor necrosis factor-alpha gene expression in murine tissue macrophages. Mol Pharmacol 52:421–429PubMed
34.
go back to reference Shi X, Ding M, Dong Z et al. (1999) Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production. Mol Cell Biochem 199:93–102CrossRefPubMed Shi X, Ding M, Dong Z et al. (1999) Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production. Mol Cell Biochem 199:93–102CrossRefPubMed
35.
go back to reference Weissmann G (1991) Aspirin. Sci Am 264:84–90 Weissmann G (1991) Aspirin. Sci Am 264:84–90
36.
go back to reference Tegeder I, Pfeilschifter J, Geisslinger G (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15:2057–2072CrossRefPubMed Tegeder I, Pfeilschifter J, Geisslinger G (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15:2057–2072CrossRefPubMed
37.
go back to reference Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL (2001) Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and IL-1β exposed human and rat islet cells. Diabetologia 44:325–332CrossRefPubMed Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL (2001) Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and IL-1β exposed human and rat islet cells. Diabetologia 44:325–332CrossRefPubMed
38.
go back to reference Hillson JL, Furst DE (2000) Rofecoxib. Expert Opin Pharmacother 1:1053–1066PubMed Hillson JL, Furst DE (2000) Rofecoxib. Expert Opin Pharmacother 1:1053–1066PubMed
39.
go back to reference Atkinson HG (2002) COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs. Health News 8:5 Atkinson HG (2002) COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs. Health News 8:5
40.
go back to reference Clark DA, Coker R (1998) Transforming growth factor-beta (TGF-beta). Int J Biochem Cell Biol 30:293–298CrossRefPubMed Clark DA, Coker R (1998) Transforming growth factor-beta (TGF-beta). Int J Biochem Cell Biol 30:293–298CrossRefPubMed
41.
go back to reference Lin JY, Seguin R, Keller K, Chadee K (1995) Transforming growth factor-beta 1 primes macrophages for enhanced expression of the nitric oxide synthase gene for nitric oxide-dependent cytotoxicity against Entamoeba histolytica. Immunology 85:400–407PubMed Lin JY, Seguin R, Keller K, Chadee K (1995) Transforming growth factor-beta 1 primes macrophages for enhanced expression of the nitric oxide synthase gene for nitric oxide-dependent cytotoxicity against Entamoeba histolytica. Immunology 85:400–407PubMed
42.
go back to reference Prud'homme GJ, Lawson BR, Theofilopoulos AN (2001) Anticytokine gene therapy of autoimmune diseases. Expert Opin Biol Ther 1:359–373PubMed Prud'homme GJ, Lawson BR, Theofilopoulos AN (2001) Anticytokine gene therapy of autoimmune diseases. Expert Opin Biol Ther 1:359–373PubMed
43.
go back to reference Mandrup-Poulsen T (1996) The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 39:1005–1029PubMed Mandrup-Poulsen T (1996) The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 39:1005–1029PubMed
44.
go back to reference Granowitz EV, Vannier E, Poutsiaka DD, Dinarello CA (1992) Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: II. IL-1 receptor antagonist inhibits lipopolysaccharide-induced cytokine synthesis by human monocytes. Blood 79:2364–2369PubMed Granowitz EV, Vannier E, Poutsiaka DD, Dinarello CA (1992) Effect of interleukin-1 (IL-1) blockade on cytokine synthesis: II. IL-1 receptor antagonist inhibits lipopolysaccharide-induced cytokine synthesis by human monocytes. Blood 79:2364–2369PubMed
45.
go back to reference Joosten LA, Helsen MM, van de Loo FA, van den Berg WB (1996) Anti-cytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 39:797–809PubMed Joosten LA, Helsen MM, van de Loo FA, van den Berg WB (1996) Anti-cytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 39:797–809PubMed
46.
go back to reference Eiririk DL, Flodström M, Karlsen AE, Welsh N (1996) The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetologia 39:875–890PubMed Eiririk DL, Flodström M, Karlsen AE, Welsh N (1996) The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetologia 39:875–890PubMed
47.
go back to reference Hammond RA, Hannon R, Frean SP, Armstrong SJ, Flower RJ, Bryant C (1999) Endotoxin induction of nitric oxide synthase and cyclooxygenase-2 in equine alveolar macrophages. Am J Vet Res 60:426–431PubMed Hammond RA, Hannon R, Frean SP, Armstrong SJ, Flower RJ, Bryant C (1999) Endotoxin induction of nitric oxide synthase and cyclooxygenase-2 in equine alveolar macrophages. Am J Vet Res 60:426–431PubMed
48.
go back to reference Gallo O, Fabbroni V, Sardi I, Magnelli L, Boddi V, Franchi A (2002) Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas. Biochem Biophys Res Commun 299:517–524CrossRefPubMed Gallo O, Fabbroni V, Sardi I, Magnelli L, Boddi V, Franchi A (2002) Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas. Biochem Biophys Res Commun 299:517–524CrossRefPubMed
Metadata
Title
Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents
Authors
C. Gysemans
K. Stoffels
A. Giulietti
L. Overbergh
M. Waer
M. Lannoo
U. Feige
Dr. C. Mathieu
Publication date
01-08-2003
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2003
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1154-0

Other articles of this Issue 8/2003

Diabetologia 8/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.